LabCorp Enhances Cancer Testing Capability With $600 Mil. Dianon Purchase
This article was originally published in The Gray Sheet
Executive Summary
LabCorp says it does not foresee antitrust issues with the Federal Trade Commission related to the acquisition of cancer testing firm Dianon